The infiltrate persisted with the addition of a MEK inhibitor (trametinib) to dabrafenib, which was also associated with an increase in CD4+, CD8+ and PD-1+ T cells, as well as in programmed death-ligand 1 (PD-L1) expression on tumor cells8. This evidence concerns the gene CD4 and neoplasm.